# ATR 1072 in Participants With PRKAG2 Syndrome

> **NCT07738107** · PHASE1,PHASE2 · RECRUITING · sponsor: **Atrium Therapeutics** · enrollment: 37 (estimated)

## Conditions studied

- Cardiac Glycogenosis
- Cardiomyopathy
- Hypertrophic
- Wolff-Parkinson-White Syndrome

## Interventions

- **DRUG:** ATR 1072

## Key facts

- **NCT ID:** NCT07738107
- **Lead sponsor:** Atrium Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-14
- **Primary completion:** 2028-05
- **Final completion:** 2028-10
- **Target enrollment:** 37 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07738107

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07738107, "ATR 1072 in Participants With PRKAG2 Syndrome". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07738107. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*